Early Feasibility Study of the Orion Visual Cortical Prosthesis System

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-20

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an early feasibility study of a new device, the Orion Visual Cortical Prosthesis System. The device is intended to stimulate the surface of the visual cortex to induce visual perception in blind individuals.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Feasibility of Stimulating the Visual Cortex in Blind

NCT02747589

Blindness,Acquired

ACTIVE_NOT_RECRUITING NA

Continued Study of Artificial Vision: Evaluation of the BrainPort® System and Investigation of Visual Ambulation

NCT02643238

Blindness

COMPLETED NA

Environmental Localization Mapping and Guidance for Visual Prosthesis Users

NCT04359108

Retinitis Pigmentosa Visual Impairment Visual Prosthesis

COMPLETED NA

Experimental and Clinical Studies of Retinal Stimulation

NCT03635645

Retinitis Pigmentosa

RECRUITING NA

Use of a Vibrotactile Sensory Prosthesis in Patients With Postural Imbalance and Spatial Disorientation

NCT00146952

Vestibular Diseases Peripheral Neuropathies Proprioceptive Disorders +1 more

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study, 6 subjects with bare light or no light perception in both eyes will be implanted with the Orion Cortical Visual Prosthesis System. The study will evaluate the safety of the device and surgery, as well as reliability of the system and the usefulness of any restored vision. Each subject will be followed for 6 years, with their health monitored throughout. Research sessions, visual function testing, and subject-reported outcomes will be used to evaluate the functioning of the system.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blindness, Acquired

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DEVICE_FEASIBILITY

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single Arm

Implanted with the Orion Visual Cortical Prosthesis System

Group Type EXPERIMENTAL

Orion Visual Cortical Prosthesis System

Intervention Type DEVICE

The Orion Visual Cortical Prosthesis System is intended to stimulate the medial surface of the occipital lobe in the visual cortex to induce visual perception in blind individuals.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Orion Visual Cortical Prosthesis System

The Orion Visual Cortical Prosthesis System is intended to stimulate the medial surface of the occipital lobe in the visual cortex to induce visual perception in blind individuals.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is bilaterally blind with bare or no light perception. This is defined as non-measurable binocular visual acuity or 5° or less visual field in each eye.
2. Subject is bilaterally blind due to:

1. Trauma to the eye, or
2. Disease or damage of the retina (such as retinopathy, retinal vein occlusion, inherited retinal diseases or retinal detachment), or
3. Disease or damage of the optic nerve or chiasm (such as glaucoma, methanol intoxication, autoimmune neuropathies, pituitary pathology, and hereditary neuropathies)
3. Subject's vision cannot be restored with any approved medication or intervention.
4. Subject has a documented history of useful form vision.
5. Subject is between the age of 22-74 .
6. Subject resides within 2 hours (by ground transportation) of the investigational site.
7. Subject is (a) male or (b) a female of childbearing potential with a negative pregnancy test who is using a reliable method of contraception or (c) a female who is at least two years post-menopause or otherwise unable to bear children.
8. Subject is able to complete regular office and telephone appointments per the protocol requirements.
9. Subject is medically fit for neurosurgical intervention.

Exclusion Criteria

1. Subject is at high risk for surgical complications such as active systemic infection, coagulation disorders (such as the use of anti-thrombotic therapies) or platelet count below 100,000.
2. Subject has history of bleeding or immune compromise.
3. Subject is taking chronic anticoagulants or antiplatelet agent or subject has an abnormally elevated preoperative coagulation profile (either PTT or PT/INR).
4. Subject has had prior craniotomy or brain surgery that would interfere with placement or function of Orion device.
5. Subject has evidence of active intracranial disease that would preclude elective neurosurgical intervention, such as unruptured intracranial aneurysm or brain tumor, or aberrant visual cortex anatomy, such as prior stroke or arteriovenous malformation.
6. Subject has a significant abnormality on preoperative brain MRI.
7. Subject has a prior history of seizures or epilepsy.
8. Subject has Parkinson's disease.
9. Subject has a prior history of serious head injury with loss of consciousness for more than 24 hours.
10. Subject has a progressive central nervous system disease.
11. Subject has a history of implant-related infection.
12. Subject requires or is likely to require any of the following medical procedures while implanted with the Orion System: MR imaging, diathermy, electroconvulsive therapy (ECT), or transcranial magnetic stimulation (TMS). These medical procedures are contraindicated for subjects implanted with an Orion System. Energy from these procedures can be sent through the implanted brain stimulation system and cause permanent brain damage which may cause severe injury, coma, or death.
13. Subject is implanted with any neurostimulation or neuromodulation device in the head including, but not limited to cochlear implant, deep brain stimulator, or auditory brain implant.
14. Subject has a clinically significant or unstable medical condition including uncontrolled systemic hypertension with values above 170/100; cardiac or pulmonary disease; uncorrected coagulation abnormalities; diabetes; or any condition that would render the patient unable to safely cooperate with the study tests as judged by the screening physician.
15. Subject has had an alcohol or illicit substance use disorder within the last 6 months, unstable remission of substance abuse, or chart evidence that co-morbid substance use disorder could account for lack of treatment response.
16. Subject has uncontrolled chronic pain.
17. Subject has significant neurocognitive impairment in memory domain (based on MoCA-BLIND \<18 or WAIS-IV \<80, described below).
18. Subject had moderate or severe depression, as determined by a score of at least 17 on the HAM-D.
19. Subject has had a suicide attempt in the last two years, presence of a suicide plan (an answer of "Yes" to Question C4 in Section C-Suicidality of MINI International Neuropsychiatric Interview), or a "yes" answer to any one of the ten suicidal ideation and behavior questions on the C-SSRS.
20. Subject has a disease or condition that prevents understanding or communication of informed consent, study demands, or testing protocols, including:

1. Cognitive decline including diagnosed forms of dementia and/or progressive neurologic disease
2. Psychiatric disease including diagnosed forms of depression
3. Does not speak a principal language associated with the region
4. Deafness or selective frequency hearing loss that prevents adequate communication with the researchers.
21. Subject has a balance disability or frequently participates in contact sports.
22. Subject must administer diathermy as part of his/her livelihood.
23. Subject is pregnant or is planning on becoming pregnant in the next year.
24. Subject has unrealistic expectations of the benefits of the study.
25. Subject is enrolled in another therapeutic investigational drug or device trial

Minimum Eligible Age

22 Years

Maximum Eligible Age

74 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No